Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Chi-Sheng Shia"'
Publikováno v:
Journal of Functional Foods, Vol 5, Iss 3, Pp 1414-1420 (2013)
Methotrexate (MTX) is an important immunosuppressant with narrow therapeutic window. The transport of MTX was associated with multi-drug resistance proteins (MRPs) and breast cancer resistance protein (BCRP). Noni fruit is a phenolics rich health foo
Externí odkaz:
https://doaj.org/article/61d207beab534450876e018efdc48e8f
Autor:
Chi-Sheng Shia, 夏麒盛
97
This study investigated the metabolism and pharmacokinetics of monohydroxyflavones, anthraquinones and San-Huang-Xie-Xin-Tang (SHXXT). Following oral administrations of 5-hydroxyflavone and 7-hydroxyflavone in rats, the glucuronide of 5-hydro
This study investigated the metabolism and pharmacokinetics of monohydroxyflavones, anthraquinones and San-Huang-Xie-Xin-Tang (SHXXT). Following oral administrations of 5-hydroxyflavone and 7-hydroxyflavone in rats, the glucuronide of 5-hydro
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/97513484289898881685
Autor:
CHI-SHENG SHIA, 夏麒盛
91
Fisetin is a bioactive natural flavonoid. In this study, the pharmacokinetics of fisetin was investigated in rats. The serum concentrations of fisetin were assayed by HPLC method after incubation at 37℃ for 6 hours with glucuronidase or 4 h
Fisetin is a bioactive natural flavonoid. In this study, the pharmacokinetics of fisetin was investigated in rats. The serum concentrations of fisetin were assayed by HPLC method after incubation at 37℃ for 6 hours with glucuronidase or 4 h
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/08332463688895141199
Autor:
Apostolia Maria Tsimberidou, Claire F. Verschraegen, Robert Wesolowski, Chi-Sheng Shia, Pei Hsu, Tillman E. Pearce
Publikováno v:
British Journal of Cancer.
Background Report of a Phase 1 dose-escalation study of OBI-3424 monotherapy in patients with advanced solid tumors (NCT03592264). Methods A classic 3 + 3 design was used to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of
Autor:
Ming-Tain Lai, Cheng-Der Yu, Jiann-Shiun Lai, Nan-Hsuan Wang, Yueh-Chin Wu, Chi-Huan Lu, Hui-Wen Chang, Yu-Jung Chen, Teng-Yi Huang, I-Ju Chen, Chun-Chung Wang, Wan-Fen Li, Chi-Sheng Shia, Ming-Chen Yang
Supplementary Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcba16014f579e89354c9b3b53f5503c
https://doi.org/10.1158/1535-7163.22522797
https://doi.org/10.1158/1535-7163.22522797
Autor:
Ming-Tain Lai, Cheng-Der Yu, Jiann-Shiun Lai, Nan-Hsuan Wang, Yueh-Chin Wu, Chi-Huan Lu, Hui-Wen Chang, Yu-Jung Chen, Teng-Yi Huang, I-Ju Chen, Chun-Chung Wang, Wan-Fen Li, Chi-Sheng Shia, Ming-Chen Yang
Supplementary Figures and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec703d5b83c795ac018834b8be04b3f
https://doi.org/10.1158/1535-7163.22522800
https://doi.org/10.1158/1535-7163.22522800
Autor:
Richard B. Lock, Malcolm A. Smith, Beverly A. Teicher, Tillman Pearce, Chi-Sheng Shia, Charles G. Mullighan, Kathryn G. Roberts, Komal S. Rathi, Donald Jung, Fanying Meng, Yuelong Guo, Stephen W. Erickson, Chelsea Mayoh, Narimanne El-Zein, Cara E. Toscan, Zhaohui Gu, Lisa McDermott, Connor D. Jones, Tara Pritchard, JianXin Duan, Kathryn Evans
Purpose:OBI-3424 is a highly selective prodrug that is converted by aldo-keto reductase family 1 member C3 (AKR1C3) to a potent DNA-alkylating agent. OBI-3424 has entered clinical testing for hepatocellular carcinoma and castrate-resistant prostate c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1054e7a9f8ca25f82d9d09add67f38
https://doi.org/10.1158/1078-0432.c.6527832.v1
https://doi.org/10.1158/1078-0432.c.6527832.v1
Autor:
Apostolia Maria Tsimberidou, Henry Hiep Vo, Jennifer Beck, Chi-Sheng Shia, Pei Hsu, Tillman E. Pearce
Publikováno v:
JCO Precision Oncology.
PURPOSE OBI-999 is a novel antibody-drug conjugate comprising the Globo H–targeting antibody (OBI-888) linked to the cytotoxic payload monomethyl auristatin E. OBI-999 demonstrated excellent dose-dependent tumor growth inhibition in breast, gastric
Autor:
Fanying, Meng, Wan-Fen, Li, Donald, Jung, Chun-Chung, Wang, Tianyang, Qi, Chi-Sheng, Shia, Ren-Yu, Hsu, Yin-Cheng, Hsieh, Jianxin, Duan
Publikováno v:
Am J Cancer Res
AST-3424/OBI-3424 (denoted by 3424) is a novel prodrug bis-alkylating agent activated by AKR1C3. AKR1C3 is overexpressed in many types of cancer, particularly in liver, non-small cell lung, gastric, renal and CRPC cancer. Currently 3424 is being stud
Autor:
Cheng-Der Yu, Hui-Wen Chang, Chi-Sheng Shia, Teng-Yi Huang, Jiann-Shiun Lai, Yueh-Chin Wu, I-Ju Chen, Wan-Fen Li, Yu-Jung Chen, Nan-Hsuan Wang, Chun-Chung Wang, Chi-Huan Lu, Ming-Tain Lai, Ming-Chen Yang
Publikováno v:
Molecular cancer therapeutics. 20(6)
Globo H (GH), a hexasaccharide, is expressed at low levels in normal tissues but is highly expressed in multiple cancer types, rendering it a promising target for cancer immunotherapy. OBI-999, a novel antibody–drug conjugate, is derived from a con